Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-MAPT, the company’s investigational RNA interference (RNAi) ...
Investing.com -- Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) stock surged 14.7% Monday after the company announced it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-MAPT, its ...
Development of RNAi-Based Therapeutics using Dynamic Polyconjugates™ (DPC™) Technology," Bruce Given, M.D., Arrowhead's chief operating officer, discussed three examples of Arrowhead's broad RNAi ...
Arrowhead Research Receives Notice of Patent Allowance for New Formulation of DPC siRNA Delivery System Showing 500-Fold Increase in Potency PASADENA, Calif. — October 16, 2012 — Arrowhead Research ...
Those looking for food deliveries from the regional Arrowhead Delivery will now have to direct orders through a different app. Bite Squad, a Minneapolis-based restaurant delivery service, announced ...
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it has nominated ARC-HIF2 as ...
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today presented an overview of its broad RNAi ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback